|Company name||Dova Pharmaceuticals, Inc.|
NEW YORK, September 30, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on behalf of Dova shareholders concerning the proposed merger with Swedish Orphan Biovitrum AB.
Pursuant to the proposed transaction, announced on September 30, 2019 and valued at $915 million, Dova shareholders will receive $27.50 in cash for each share of Dova common stock owned. Additionally, Dova shareholders will be entitled to one non-tradeable CVR of $1.50 per share upon the regulatory approval of DOPTELET, a treatment for CIT. The investigation focuses on whether Dova and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Dova shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Alexandra Raymond by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.